Home
NewsNewsBirths resulting from essential Infertility Treatments, including advanced procedures like artificial insemination and IVF, have seen a very positive and promising climb, accounting for almost 15.1% of the total births recorded in 2024.
Two years ago, in 2024, one in seven newborns was born via infertility treatments like artificial insemination or in vitro fertilization – IVF as per a study in Korea. The proportion with regard to multiple births, including twins, has also seen a growth.
Confirms Study on Analysis of Side Effects of Infertility Treatments and Preparation of Management Plans from Health Insurance Review & Assessment Service, 36,025 out of 238,235 total births in 2024, which is about 15.1%, took place due to infertility treatments.
While the overall number of births saw a dip of 21.1% in a matter of five years, from 302,348 that were recorded in 2019 to 238,235 in 2024, rise in births with infertility treatments in Korea saw a jump of 36.6%, from 26,371 to 36,025. Notably, the proportion of births via infertility treatments almost doubled, rising from 8.7% to 15.1% between 2019 and 2024.
It is worth noting that the increase when it comes to infertility treatments has also gone on to raise the multiple birth rate. The size of multiple births across all the newborns grew from 4.6% in 2019 to 5.7% in 2024.
The rise in births with infertility treatments in Korea is due to the increasing age of marriage as well as childbirth, in addition to the health insurance coverage expansion when it comes to infertility treatments.
The proportion of multiple births in infants that were born by way of infertility treatments saw a slight dip from 35.5% in 2019 to 27.3% in 2024. But this does remain significantly higher as compared to the 1.6–1.8% rate for multiple births due to natural pregnancies. Apparently, the likelihood of multiple pregnancies increases when many embryos are transferred at the time of infertility treatment in order to enhance the success rates. The major dip when it comes to multiple births is attributed to the rising awareness of risks like maternal complications and also cerebral palsy in infants, thereby leading more parents to choose single-embryo transfers.
A professor of obstetrics and gynecology at the Seoul National University Hospital and also president of the Korean Maternal-Fetal Medicine Society, Park Jung-shin, said, “When undergoing infertility treatments, the various high-risk factors associated with multiple pregnancies must be thoroughly considered.”
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
